Vercise Genus™ DBS System
Precision Takes Shape
Easily customize therapy to match each patient’s needs with the Vercise Genus DBS system. Featuring an MR conditional portfolio and miniaturized components, Vercise Genus delivers the next level of precision in directional stimulation, without compromise.
The Vercise Genus DBS System offers unmatched precision, flexibility and control. Our unique therapy options and advanced programming features are designed to make it easier than ever to manage patient's symptoms.
Our patient-centered portfolio prioritizes patient comfort and convenience. Taken together, the benefits of the Vercise Genus DBS System allow your patients to see a brighter tomorrow take shape.
Two Lead Options: A Directional and Standard Lead
The Vercise Genus DBS System delivers the next level of precision in directional stimulation, without compromise, with the Vercise Cartesia™ Directional lead. The Vercise Cartesia Directional lead offers flexibility to optimize patient therapy while avoiding side effects.
The Vercise standard lead offers the best of both span and spacing, with eight ring contacts.
At least 15 Year Battery Life** on Rechargeable IPGs
The Vercise Genus rechargeable IPGs offer easy wireless charging designed to fit seamlessly into patient routines. The Zero-Volt™ battery technology is specifically engineered to maintain capacity and resist corrosion over years of recharging.
Streamlined Approach to Personalized DBS Programing
Vercise™ Neural Navigator 4 Programming Software features secure, wireless Bluetooth communication, intuitive directional steering controls, visualization of stimulation field modeling and insightful clinical effect annotations.
The Vercise Genus DBS System features directional and standard leads powered by Cartesia 3D.
Precision Made Personal
All of the system’s IPGs are full-body
MR conditional*** and powered by Cartesia 3D directional programming.
The Vercise DBS systems are supported by dozens of studies with hundreds of patients showing clinical benefits to patients globally.